厄贝沙坦联合心可舒治疗腹型肥胖合并原发性高血压高、血脂患者的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Irbesartan combined with Xinkeshu in the treatment of patients with abdominal obesity complicated with essential hypertension and hyperlipidemia.Methods One hundred patients with abdominal obesity complicated with essential hypertension and hyperlipidemia who were treated in our hospital from June 2017 to September 2018 were selected as subjects.According to the different treatment methods, they were divided into experimental group and control group, each group with 50 cases.Patients in the experimental group were treated with Irbesartan combined with Xinkeshu, while patients in the control group were treated with Irbesartan alone.The therapeutic effect, blood pressure and blood lipid before and after treatment were compared between the two groups.Results The total effective rate in the control group was 90.0%, and the total effective rate in the experimental group was 92.0%.There was no significant difference in the total effective rate between the two groups (P＞0.05).After treatment, the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the two groups were lower than before, and the differences were statistically significant (P＜0.05).There were no significant differences in SBP and DBP between the two groups after treatment (P＞0.05).After treatment, the triglyceride (TG), total cholesterol (TC) and lowdensity lipoprotein cholesterol (LDL-C) in the two groups were all lower than before treatment, with statistically significant differences (P＜0.05).The TG, TC and LDL-C in the experimental group were lower than those in the control group after treatment, with statistically significant differences (P＜0.05).Conclusion Xinkeshu could not effectively reduce the blood pressure of patients in terms of treatment, but compared with Irbesartan alone, Xinkeshu could improve the blood lipid level in patients.The combined use of Xinkeshu and Irbesartan in the treatment of patients with abdominal obesity complicated with essential hypertension and hyperlipidemia, can achieve a better effect, which is worthy of being popularized and applied in clinical treatment.

Key words： Irbesartan Essential hypertension Blood lipid Clinical treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Juan-feng
	WANG Li-jun
	WANG Ping

Cite this article:

LIU Juan-feng,WANG Li-jun,WANG Ping. Clinical effect of Irbesartan combined with Xinkeshu in the treatment of patients with abdominal obesity complicated with essential hypertension and hyperlipidemia[J]. 中国当代医药, 2020, 27(3): 84-87.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I3/84

[1]	邱福美，谢怀全，陈国华，等.厄贝沙坦联合硝苯地平治疗原发性高血压的效果及对患者左心室舒张功能和生活质量的影响[J].中国临床新医学，2019，15（2）：197-200.
[2]	詹灵.厄贝沙坦联合硝苯地平治疗原发性高血压的效果观察[J].心血管病防治知识，2019，9（26）：5-7.
[3]	龚芸.厄贝沙坦联合小剂量利尿剂对老年单纯收缩期高血压患者血清炎症因子及血管内皮功能的影响[J].实用临床医药杂志，2019，23（4）：54-56.
[4]	秦静.硝苯地平控释片联合厄贝沙坦在社区糖尿病合并高血压患者治疗中的效果观察[J].世界最新医学信息文摘，2019，19（13）：134.
[5]	刘利勤，李青，胡明，等.应用Markov 模型对3 种血管紧张素Ⅱ受体拮抗剂预防高血压患者卒中和心肌梗死的经济学评价[J].中国药学杂志，2019，54（2）：137-143.
[6]	徐梅.硝苯地平缓释片联合厄贝沙坦在社区糖尿病合并高血压患者治疗中的应用价值评价[J].糖尿病新世界，2019，22（2）：75-76.
[7]	吴建国.厄贝沙坦联合氨氯地平对老年高血压患者血压变异性及血管内皮细胞功能的影响[J].慢性病学杂志，2019，20（1）：49-50.
[8]	王苏芳.厄贝沙坦氢氯噻嗪分散片与缬沙坦氨氯地平片治疗高血压合并非酒精性脂肪肝患者的效果比较[J].中外医学研究，2018，16（36）：10-12.
[9]	程炎炎，张璇，余瑶.护理干预对厄贝沙坦氢氯噻嗪治疗原发性高血压临床效果的影响[J].当代护士（中旬刊），2018，25（32）：27-28.
[10]	计晓辉.硝苯地平控释片联合厄贝沙坦氢氯噻嗪片治疗94 例中重度高血压的临床研究[J].北方药学，2019，10（5）：75-76.
[11]	汪茶花.硝苯地平联合厄贝沙坦治疗青年原发性高血压的临床效果分析[J].基层医学论坛，2019，23（13）：1916-1917.
[12]	陈光泽，温巧，向四国.厄贝沙坦联合氨氯地平治疗老年高血压的效果分析[J].中国处方药，2019，9（4）：79-80.
[13]	邓飞，邢风雷，吴娟鸽.厄贝沙坦联合螺内酯治疗慢性心力衰竭患者的临床疗效及其对炎性因子、自主神经功能的影响研究[J].实用心脑肺血管病杂志，2019，27（2）：89-92.
[14]	刘莉.硝苯地平联合厄贝沙坦片与比索洛尔联合硝苯地平治疗原发性高血压临床分析[J].中西医结合心血管病电子杂志，2019，7（10）：26.
[15]	魏华伟.美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的疗效研究[J].临床研究，2019，27（4）：90-92.